Biomarkers for Palbociclib in Fulvestrant-Resistant Metastatic Breast Cancer Using cfDNA Cancer Panel Sequencing

被引：0
|
作者：
Takeshita, Takashi [1 ]
Iwamoto, Takayuki [2 ]
Niikura, Naoki [3 ]
Watanabe, Kenichi [4 ]
Kikawa, Yuichiro [5 ]
Kobayashi, Kokoro [6 ]
Okamura, Takuho [3 ]
Tada, Hiroshi [7 ]
Ozaki, Shinji [8 ]
Toh, Uhi [9 ]
Yamamoto, Yutaka [1 ]
Tsuneizumi, Michiko [10 ]
Ishiguro, Hiroshi [11 ]
Masuda, Norikazu [12 ]
Saji, Shigehira [13 ]
机构：
[1] Kumamoto City Hosp, Dept Breast & Endcrine Surg, Kumamoto, Japan
[2] Kawasaki Med Sch Hosp, Dept Breast & Thyroid Surg, Kawasaki, Japan
[3] Tokai Univ, Sch Med, Dept Breast Oncol, Tokai, Japan
[4] NHO Hokkaido Canc Ctr, Det Breast Oncol, Sapporo, Japan
[5] Kansai Med Univ Hosp, Dept Breast Surg, Hirakata, Japan
[6] Saitama Red Cross Hosp, Dept Med Oncol, Saitama, Japan
[7] Tohoku Univ Hosp, Dept Breast & Endocrine Surg, Sendai, Japan
[8] Hiroshima Prefectural Hosp, Dept Gastrointestinal & Breast Surg, Hiroshima, Japan
[9] Kurume Univ, Hosp Dept Breast Surg, Kurume, Japan
[10] Shizuoka Prefectural Gen Hosp, Dept Breast Surg, Shizuoka, Japan
[11] Saitama Med Univ, Int Med Ctr, Breast Oncol Serv, Saitama, Japan
[12] Kyoto Univ, Grad Sch, Dept Breast Surg, Med Div, Kyoto, Japan
[13] Fukushima Med Univ, Sch Med, Dept Med Oncol, Fukushima, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E-3050
引用
收藏
页码：1890 / 1890
页数：1
相关论文
共 50 条
  • [41] FULVESTRANT FOR METASTATIC BREAST CANCER: EXPERIENCE WITH 74 PATIENTS
    Mello, C. A. L.
    Silva, S. C. S.
    Chinen, L. T. D. C.
    Fregnani, J. H. T.
    Choi, R.
    Martins, S. J.
    Levy, A. C. S.
    Matias, C. N.
    Gimenes, D. L.
    Fanelli, M. F.
    ANNALS OF ONCOLOGY, 2008, 19 : 75 - 75
  • [42] The safety and efficacy of palbociclib in the treatment of metastatic breast cancer
    Ettl, Johannes
    Harbeck, Nadia
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (08) : 661 - 668
  • [43] Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2-Advanced/Metastatic Breast Cancer
    Seki, Hirohito
    Sakurai, Takashi
    Maeda, Yuka
    Oki, Naohiko
    Aoyama, Mina
    Yamaguchi, Ryou
    Tokuda, Toshiki
    Kaburagi, Takuji
    Okumura, Takehiro
    Karahashi, Tsuyoshi
    Nakajima, Kenichiro
    Higeta, Kaori
    Shimizu, Ken
    IN VIVO, 2019, 33 (06): : 2037 - 2044
  • [44] Evaluation of segurity of Palbociclib in the treatment of metastatic breast cancer
    Moreno, P.
    Rodriguez, P.
    Alvarez, R.
    Rodriguez, A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 369 - 369
  • [45] Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis
    Chirila, Costel
    Mitra, Debanjali
    Colosia, Ann
    Ling, Caroline
    Odom, Dawn
    Iyer, Shrividya
    Kaye, James A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (08) : 1457 - 1466
  • [46] Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial
    Malorni, Luca
    Tyekucheva, Svitlana
    Hilbers, Florentine S.
    Ignatiadis, Michail
    Neven, Patrick
    Colleoni, Marco
    Henry, Stephanie
    Ballestrero, Alberto
    Bonetti, Andrea
    Jerusalem, Guy
    Papadimitriou, Konstantinos
    Bernardo, Antonio
    Duhoux, Francois
    MacPherson, Iain
    Thomson, Alastair
    Davies, David Mark
    Bergqvist, Mattias
    Benelli, Matteo
    McCartney, Amelia
    De Swert, Heidi
    Ruepp, Barbara
    Rabaglio, Manuela
    Maibach, Rudolf
    Piccart, Martine
    Regan, Meredith M.
    CANCER RESEARCH, 2021, 81 (04)
  • [47] Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR +, HER2-metastatic breast cancer
    Loibl, S.
    Demichele, A.
    Turner, N. M.
    Cristofanilli, M.
    Loi, S.
    Verma, S.
    Bhattacharyya, H.
    Ke, Z.
    Giorgetti, C.
    Bartlett, C. H.
    Iyer, S.
    Colleoni, M.
    Masuda, N.
    Im, S-A.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2016, 27
  • [48] Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
    Sunil Pancholi
    Nikiana Simigdala
    Ricardo Ribas
    Eugene Schuster
    Mariana Ferreira Leal
    Joanna Nikitorowicz-Buniak
    Camilla Rega
    Teeru Bihani
    Hitisha Patel
    Stephen R. Johnston
    Mitch Dowsett
    Lesley-Ann Martin
    npj Breast Cancer, 8
  • [49] Loss of ERα involved-HER2 induction mediated by the FOXO3a signaling pathway in fulvestrant-resistant breast cancer
    Karouji, Kento
    Tominari, Tsukasa
    Abe, Reika
    Sugasaki, Moe
    Ikeda, Keisuke
    Matsumoto, Chiho
    Miyaura, Chisato
    Miyata, Shinji
    Nomura, Yoshihiro
    Itoh, Yoshifumi
    Hirata, Michiko
    Inada, Masaki
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2025, 742
  • [50] Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells
    Warth, Benedikt
    Palermo, Amelia
    Rattray, Nicholas J. W.
    Lee, Nathan, V
    Zhu, Zhou
    Hoang, Linh T.
    Cai, Yuping
    Mazurek, Anthony
    Dann, Stephen
    VanArsdale, Todd
    Fantin, Valeria R.
    Shields, David
    Siuzdak, Gary
    Johnson, Caroline H.
    METABOLITES, 2019, 9 (01)
12345